Retatrutide Peptide Profile
A single reference page for the peptide itself: what it is called, what class it belongs to, what it targets, and how it is supplied and verified as laboratory material.
Key concepts
- LY3437943 is the research designation
- Lipidated incretin-family peptide, three receptor targets
- Lyophilised supply, third-party assayed per batch
- Record batch, purity and diluent with every result
- Match the vial batch number to the published certificate before use
- This profile is a research summary, not a pharmacopoeial specification
Peptide reference table
The table below collects the identifiers and properties most often needed when recording retatrutide in a laboratory notebook or method section.
| Property | Detail |
|---|---|
| Common name | Retatrutide |
| Research designation | LY3437943 |
| Class | Lipidated synthetic incretin-family peptide |
| Receptor targets | GIP, GLP-1 and glucagon receptors (triple agonist) |
| Structural strategy | Sequence stabilisation plus fatty-acid side chain for albumin binding |
| Supplied format | Lyophilised powder in a sealed glass vial |
| Batch testing | Third-party assay by Janoshik Analytical, certificate published per lot |
| Intended use | In-vitro laboratory research only |
Handling summary
Store the sealed vial cold and protected from light, reconstitute only in a suitable sterile aqueous diluent, and avoid repeated freeze-thaw cycles once in solution. Aliquot reconstituted material rather than returning the same vial to the freezer repeatedly.
Verify each batch against the published certificate of analysis before use, and record batch number, purity and reconstitution diluent alongside experimental results so that potency values remain traceable.
Scope of supply
Retatrutide supplied by Biovanta Research is laboratory material for in-vitro research by qualified persons. It is not a medicine, not for human or veterinary use, and no dosing guidance is given.
Verifying a batch before use
A certificate of analysis is only useful if it is checked against the specific vial in hand. Confirm that the batch number printed on the vial matches the batch number on the published certificate, that the analytical method used, typically HPLC and mass spectrometry, is stated, and that the purity figure and identity confirmation are both present before the material is logged into a laboratory’s own inventory.
Where a certificate is missing, out of date, or does not match the batch number on the vial, the material should not be treated as verified and the supplier should be asked to provide current documentation before use.
What to record in the laboratory notebook
Beyond the certificate itself, a reproducible record should capture the reconstitution diluent and final concentration, the date of reconstitution, the storage temperature and duration between freeze-thaw events, and the assay or model system in which the material was subsequently used. This level of detail is what allows a result to be traced back to a specific, verified batch if a finding needs to be checked or repeated.
Distinguishing this profile from a pharmaceutical specification
The reference profile above describes research-grade material intended for in-vitro laboratory use. It is not a pharmacopoeial monograph and does not carry the formulation, excipient or sterility specifications that would apply to a medicinal product. Any figure that matters for a specific experiment, including exact purity or residual solvent content, should be read from the batch-specific certificate of analysis rather than from this general summary.
Searching for further primary detail on the peptide
For structural or analytical detail beyond this summary table, the most reliable approach is to search PubMed for the compound’s non-proprietary name together with the sponsor code LY3437943, and to search ClinicalTrials.gov for the same terms to see which studies have used it and under what protocol identifiers. Analytical method papers describing HPLC or mass spectrometry characterisation of incretin-family peptides more generally are also useful background for understanding how a batch certificate of analysis for this molecule is produced and what its stated purity figure actually represents.
Any specific numerical value relevant to a particular experiment, including molecular weight to a stated number of decimal places, exact purity, or residual solvent content, should be read from the batch-specific certificate of analysis rather than from this general reference profile, which is intended as an orientation summary rather than a substitute for that document.
Developer trial material versus research-grade supply
The peptide profile summarised above describes research-grade material intended for in-vitro laboratory work. It should not be confused with drug substance manufactured for the sponsor’s clinical trial programme, which is produced under a pharmaceutical quality system, formulated for administration under trial protocol, and subject to a regulatory dossier rather than a single-page certificate of analysis. A laboratory sourcing peptide for its own research should judge the material entirely on its own batch documentation rather than by reference to the clinical programme’s manufacturing standards, since the two supply chains are not connected and one does not vouch for the other.
Reading a certificate of analysis alongside this profile
This reference profile gives the properties that are stable across batches, such as the research designation and receptor targets, but every figure that can vary from lot to lot, including exact purity, residual moisture and specific peak retention times on HPLC, belongs on the batch certificate rather than on this page. When the two documents are read together, the certificate should always take precedence for any number relevant to a specific experiment.
Strength of the current evidence
Identifiers and structural description follow the published characterisation of the molecule; format and testing details describe Biovanta Research supply and should be cross-checked against the batch-specific certificate of analysis.
References
- Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metabolism, 2022 (PubMed)
- Registered retatrutide studies (ClinicalTrials.gov search listing)
Related Retatrutide research
- What is Retatrutide? — Definition, research designation, peptide class and receptor targets of retatrutide as a laboratory research compound.
- Storage — Storage conditions for lyophilised and reconstituted retatrutide in a laboratory setting.
- Molecular Weight — Reported molecular weight of retatrutide, how it is confirmed analytically, and how to use it in reconstitution calculations.
Back to the Retatrutide research hub · Retatrutide research material · Certificates of analysis
Research use only. Everything on this page describes published laboratory and preclinical research into a compound supplied strictly for in-vitro research by qualified persons. It is not medical advice, it does not describe human or veterinary use, and no dosing guidance is given.